Summit Creek Advisors LLC lowered its stake in shares of Dolby Laboratories (NYSE:DLB – Free Report) by 8.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 113,846 shares of the electronics maker’s stock after selling 11,188 shares during the period. Summit Creek Advisors LLC’s holdings in Dolby Laboratories were worth $7,311,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Dolby Laboratories by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 7,756,924 shares of the electronics maker’s stock worth $561,369,000 after purchasing an additional 203,411 shares in the last quarter. State Street Corp raised its stake in shares of Dolby Laboratories by 8.7% during the 2nd quarter. State Street Corp now owns 2,261,059 shares of the electronics maker’s stock worth $167,906,000 after purchasing an additional 180,072 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Dolby Laboratories by 51.8% during the 2nd quarter. AQR Capital Management LLC now owns 1,736,260 shares of the electronics maker’s stock worth $128,935,000 after purchasing an additional 592,282 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Dolby Laboratories by 22.7% during the 3rd quarter. First Trust Advisors LP now owns 1,518,657 shares of the electronics maker’s stock worth $109,905,000 after purchasing an additional 281,214 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Dolby Laboratories by 8.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,149,927 shares of the electronics maker’s stock worth $83,220,000 after purchasing an additional 87,202 shares in the last quarter. Institutional investors own 58.56% of the company’s stock.
Dolby Laboratories Trading Up 1.1%
DLB opened at $53.98 on Thursday. Dolby Laboratories has a 1-year low of $52.45 and a 1-year high of $77.00. The stock’s fifty day simple moving average is $60.42 and its 200 day simple moving average is $63.50. The stock has a market cap of $5.11 billion, a PE ratio of 21.34 and a beta of 0.86.
Dolby Laboratories Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 20th. Investors of record on Tuesday, May 12th were paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, May 12th. Dolby Laboratories’s dividend payout ratio is 56.92%.
Insider Activity at Dolby Laboratories
In related news, SVP John D. Couling sold 7,666 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $57.55, for a total value of $441,178.30. Following the sale, the senior vice president owned 118,353 shares in the company, valued at approximately $6,811,215.15. This represents a 6.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Shriram Revankar sold 3,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $54.90, for a total value of $164,700.00. Following the completion of the sale, the senior vice president owned 80,603 shares in the company, valued at approximately $4,425,104.70. This trade represents a 3.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 20,249 shares of company stock worth $1,157,434. Company insiders own 37.93% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on DLB. Barrington Research reiterated an “outperform” rating and set a $90.00 price objective on shares of Dolby Laboratories in a research note on Monday, April 27th. Wall Street Zen cut Dolby Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Rosenblatt Securities reiterated a “buy” rating and set a $85.00 price objective on shares of Dolby Laboratories in a research note on Friday, January 30th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Dolby Laboratories in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $90.75.
View Our Latest Analysis on Dolby Laboratories
Dolby Laboratories Company Profile
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
Read More
- Five stocks we like better than Dolby Laboratories
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
Want to see what other hedge funds are holding DLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dolby Laboratories (NYSE:DLB – Free Report).
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
